📰 Spherix Network News
Page 2 - Spherix Network News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Spherix Network. Real-time updates on events, politics, business and more.
November 1, 2023
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun
October 13, 2023
Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have
October 4, 2023
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management
October 3, 2023
Analysis of 1,025 recently switched PsA patients reveals second- or later-line usage of IL-17, IL-23, and JAK inhibitors growing in popularity....
September 26, 2023
Exton, PA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the...
August 31, 2023
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring...
August 17, 2023
Will Pfizer’s marketing power help Zavzpret™ rapidly gain share in the crowded migraine market?...
August 15, 2023
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE treatment gold standard, Dupixent....
August 2, 2023
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease
July 28, 2023
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights...